EffRx’s management team has extensive operational experience in both Europe and the U.S., and within a range of industries and therapeutic areas. EffRx intends to fully leverage this collective experience to build a global pharmaceutical business through superior products and successful partnerships.
Chief Executive Officer
Mr. Bosisio has a track record of more than 15 years of international Marketing, Business Development and Sales across competitive markets within both blue-chip and start-up companies. Most recently he served as Chief Commercial Officer for Tissot Medical Research and as EMEA Marketing Director for Alexion. At Amgen International for 9 years, he built from scratch the commercial infrastructure for the flagship drug denosumab, launched Prolia®, optimized Aranesp® and launched Mimpara®. At PricewaterhouseCoopers Switzerland he led Marketing and Business Development for its major practice. Earlier in his career he set up the commercial organization and led Marketing & Sales for a start-up.
Mr. Bosisio holds a BSc in Economics & Business Administration and has earned an MBA from HEC School of Management Paris. Mr. Bosisio has worked and studied in Switzerland, US, France, Italy, UK and Australia and speaks English, German, French, Italian, and Spanish.
Chief Financial Officer
Mr. Paolo Agnoluzzi has been appointed as Chief Financial Officer effective June 1st, 2017. Mr. Agnoluzzi joined EffRx in August 2016 as Interim Chief Financial Officer and led the re-organization of the Finance Department. Among other achievements, he executed a number of debt and equity transactions, including a capital increase.
Most recently, Mr. Agnoluzzi served as Finance Director for VistaJet Group Holding SA. His responsibilities included acting as deputy CFO, leading the financial planning and analysis group, heading the treasury function and directing special projects within Finance.
Prior to VistaJet, Mr. Agnoluzzi held the position of Director Finance Europe and Commercial Head DACH Region at Endocyte Europe GmbH. Previously to Endocyte, he spent 20 years at Amgen serving various senior financial positions, including among others, Head of Finance Oncology, Bone and New Products and Director Finance & Administration.
Dr. Josef Hruska MD
Executive Medical Director
Dr. Hruska has over 20 years’ experience in the pharmaceutical industry, including biotechnology, on local and international roles spanning multiple therapeutic areas.
Most recently he worked as EUCAN Medical Director at Takeda Pharmaceuticals where he lead Medical Affairs activities for a novel biologic treatment for Ulcerative Colitis and Crohn’s disease. Prior to that he served as Global Brand Medical Director at Novartis Pharma for over 4 years where he led Medical Affairs activities in pediatric orphan indications as well as in osteoporosis. Dr. Hruska drove medical communication strategy for to date the biggest anti-fracture efficacy study in men. He also worked for NovoNordisk, MSD Australia and Pfizer Czech Republic. Dr. Hruska has a proven track record in Medical Affairs, Clinical Development, Life Cycle Management, Medical Communication and Education as well as Patient Support Programs.
Dr. Hruska holds an MD from Charles University in Prague as well as a specialization in Obstetrics and Gynecology.